← 返回

CD3(+)CD4(-)CD8(-)(双阴性)T 细胞在炎症、免疫紊乱和癌症中的作用

英文原题:CD3(+)CD4(-)CD8(-) (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer.

查看英文原题

CD3(+)CD4(-)CD8(-) (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer.

PubMed 2022/02/10(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD4+和CD8+T细胞在免疫疾病和癌症发展过程中塑造和控制免疫反应的关键作用已被充分确立,并用于实现显著的临床获益。CD3+CD4-CD8-双阴性(DN)T细胞虽然仅构成外周T细胞中的一个罕见亚群,但因其在炎症、免疫疾病和癌症中的作用而日益受到关注。本文全面综述了这一独特T细胞亚群的起源、分布和功能。首先,我们聚焦于表征多功能DN T细胞在各种免疫反应中的作用。DN调节性T细胞具有预防移植物抗宿主病的能力,并对自身免疫性疾病具有治疗价值。T辅助样DN T细胞根据具体环境发挥抗炎或促炎作用、抗病毒感染或促进病毒感染,并促进某些自身免疫性疾病。

值得注意的是,我们阐明了DNTIL(肿瘤浸润淋巴细胞)的作用,并概述了DN T细胞恶性增殖的潜力。最后,我们综述了基于DN T细胞疗法在癌症应用中的最新进展。

总之,更好地理解DN T细胞的异质性和功能可能有助于将DN T细胞开发为治疗炎症、免疫紊乱和癌症的潜在工具。

展开英文摘要原文

The crucial role of CD4 + and CD8 + T cells in shaping and controlling immune responses during immune disease and cancer development has been well established and used to achieve marked clinical benefits. CD3 + CD4 - CD8 - double-negative (DN) T cells, although constituting a rare subset of peripheral T cells, are gaining interest for their roles in inflammation, immune disease and cancer.

Herein, we comprehensively review the origin, distribution and functions of this unique T cell subgroup. First, we focused on characterizing multifunctional DN T cells in various immune responses. DN regulatory T cells have the capacity to prevent graft-versus-host disease and have therapeutic value for autoimmune disease. T helper-like DN T cells protect against or promote inflammation and virus infection depending on the specific settings and promote certain autoimmune disease.

Notably, we clarified the role of DN tumor-infiltrating lymphocytes and outlined the potential for malignant proliferation of DN T cells.

Finally, we reviewed the recent advances in the applications of DN T cell-based therapy for cancer.

In conclusion, a better understanding of the heterogeneity and functions of DN T cells may help to develop DN T cells as a potential therapeutic tool for inflammation, immune disorders and cancer.

论文信息

作者
Wu Z、Zheng Y、Sheng J、Han Y、Yang Y、Pan H、Yao J
单位
Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.China
文献类型
非美国政府资助研究 · 综述
期刊
Frontiers in immunology2022
原文标识
PubMed 35222392 · DOI 10.3389/fimmu.2022.816005